摘要
目的 研究乳腺癌c erbB 2改变与生存率、内分泌治疗效果及预后的关系 ,探讨有效反映乳腺癌c erbB2变化的简单检测方法。方法 半定量PCR检测c erbB2基因扩增 ;免疫组化检测c erbB2蛋白表达。随访 5 8例患者。结果 c erbB 2蛋白过表达 (+ + )与基因扩增有显著的一致性 (P<0 .0 1) ,一致率 93 .7%。c erbB2蛋白过表达 (+ + )患者的 5年生存率 (4 4.4% )显著低于c erbB 2阳性表达 (+ ) (66.7% )和c erbB 2阴性表达患者 (78.6% ) (P <0 .0 5 )。c erbB 2蛋白过表达患者服用三苯氧胺不能显著提高 5年生存率。结论 c erbB2蛋白过表达患者 5年生存率低、预后差 ,且对内分泌治疗不敏感。免疫组化可以简单、有效地检测乳腺癌c erbB2的改变。
Objective To investigate the relationship of c erbB2 with endocrine therapy and prognosis, to investigate the rapid and effective method to detect c erbB2 alteration in breast carcinoma(BC).Metheds Semi quantitative PCR was used to detect the amplification of c erbB2, and immunohistochemistry was used to detect the expression of protein of c erbB2. 58 cases of BC were followed up .Results There was significant relationship between c erbB2 protein overexpression and gene amplification(P<0.01). Five year survival rate in the patients with c erbB2 overexpression+),(44.4%)] was significant lower than that of c erbB2 positive expression was significant lower than that of c erbB2 positive expression[(+),(66.7%)] and c erbB2 negative expression[(78.6%) (P< 0.05 )]. Tamoxifen can not improve the survival rate of the patient with c erbB2 overexpression.Conclusions Patients with c erbB2 overenpression have poor prognosis and are not sensitive to endocrine therapy. Immunohistochemistry can detect the alteration of c erbB2 rapidly and effectively.
出处
《中国普通外科杂志》
CAS
CSCD
2003年第10期735-738,共4页
China Journal of General Surgery
基金
高等学校博士学科点专项科研基金(2 0 0 2 0 4 2 2 0 4 2 )
山东省自然科学基金 (9562 0 8)
